Filter results

Clinical Studies

Open

  • Real-World Data to Assess Variation in Opioid Prescribing and Use for Acute Pain in Diverse Populations Rochester, Minn.

    This is a prospective observational cohort study.

    This study will address important gaps in knowledge that hamper the development of evidence-based guidelines for acute pain management by prospectively following patients for 180 days and collecting detailed information on patients’ self-reported experience of pain and their corresponding analgesic use.

    This study will invite opioid-naïve patients receiving an opioid prescription for the treatment of acute pain in primary or urgent care, an emergency department, or a dental office. Opioid naive patients are those who self-report no opioid use in the prior 6 months. For the purpose of the study, acute pain is defined as pain that started less than 8 weeks before entry in the study. The study will follow consented patients prospectively for 180 days, tracking their pain and treatment patterns using a novel patient-centered health data sharing platform – Hugo – that will consolidate data from patient-reported outcomes, pharmacy records, and electronic health records.

Contact Us for the Latest Status

  • Real-World Data to Assess Variation in Opioid Prescribing and Use for Acute Pain in Diverse Populations Eau Claire, Wis.

    This is a prospective observational cohort study.

    This study will address important gaps in knowledge that hamper the development of evidence-based guidelines for acute pain management by prospectively following patients for 180 days and collecting detailed information on patients’ self-reported experience of pain and their corresponding analgesic use.

    This study will invite opioid-naïve patients receiving an opioid prescription for the treatment of acute pain in primary or urgent care, an emergency department, or a dental office. Opioid naive patients are those who self-report no opioid use in the prior 6 months. For the purpose of the study, acute pain is defined as pain that started less than 8 weeks before entry in the study. The study will follow consented patients prospectively for 180 days, tracking their pain and treatment patterns using a novel patient-centered health data sharing platform – Hugo – that will consolidate data from patient-reported outcomes, pharmacy records, and electronic health records.

.